Original Article

You have free access to this content

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily†‡

Two-year follow-up of a randomized phase 2 study (START-R)

  1. Hagop Kantarjian MD1,§,*,
  2. Ricardo Pasquini MD2,
  3. Vincent Lévy MD, PhD3,
  4. Saengsuree Jootar MD4,
  5. Jerzy Holowiecki MD, PhD5,
  6. Nelson Hamerschlak MD, PhD6,
  7. Timothy Hughes MD7,
  8. Eric Bleickardt MD8,
  9. David Dejardin MSc8,
  10. Jorge Cortes MD1,
  11. Neil P. Shah MD, PhD9

Article first published online: 17 JUN 2009

DOI: 10.1002/cncr.24504

Issue

Cancer

Cancer

Volume 115, Issue 18, pages 4136–4147, 15 September 2009

Additional Information

How to Cite

Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J. and Shah, N. P. (2009), Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer, 115: 4136–4147. doi: 10.1002/cncr.24504

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Hospital De Clinicas De Curitiba, Parana, Brazil

  3. 3

    Clinical Investigation Center, AP-HP, INSERM U9504, Hôpital Saint-Louis, Paris, France

  4. 4

    Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  5. 5

    University Hospital-SPSKM, Katowice, Poland

  6. 6

    Hospital Israelita Albert Einstein, Sao Paulo, Brazil

  7. 7

    Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

  8. 8

    Bristol-Myers Squibb, Wallingford, Connecticut

  9. 9

    Division of Hematology and Oncology, University of California at San Francisco School of Medicine, San Francisco, California

  1. §

    Fax: (713) 794-4297

*Department of Leukemia, Unit 428, The University of Texas M. D. Anderson Cancer Center, PO Box 301402, Houston, TX 77230-1402

  1. †

    Presented previously in part as an oral presentation at the 49th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, Georgia, December 8-11, 2007; and as a poster presentation at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 30 to June 3, 2008; and at the 13th Congress of the European Hematology Association, Copenhagen, Denmark, June 12-15, 2008.

  2. ‡

    The following principal investigators, in addition to the authors, also participated in the CA180-017 study: J. J. Garcia, I. Otero, and D. Riveros (Argentina); C. Arthur (Australia); A. Bosly and W. Schroyens (Belgium); P. E. Dorlhiac Llacer and A. Moellman Coelho (Brazil); S. Assouline, D. Forrest, C. Gambacorti-Passerini, P. Laneuville, and A. Turner (Canada); M. Varik (Estonia); K. Porkka (Finland); T. Facon, F. Guilhot, M. Michalet, J. Reiffers, and P. Rousselot (France); C. Bokemeyer, A. Hochhaus, and D. Niederwieser (Germany); T. Masszi (Hungary); A. Nagler (Israel); D. W. Kim (Korea); H. Hjorth-Hansen (Norway); L. Casanova and J. Navarro (Peru); P. Caguioa (Philippines); A. Dmoszynska, W. Jedrzejczak, A. Hellmann, T. Robak, and A. Skotnicki (Poland); F. Cabanillas (Puerto Rico); N. Khoroshko, A. Zaritsky, and A. Golenkov (Russia); J. Lombard, P. Ruff, and G. Cohen (South Africa); L. Stenke and H. Wadenvik (Sweden); L. Y. Shih (Taiwan); J. Apperley, T. Holyoake, and S. O'Brien (United Kingdom); and J. Dipersio, J. K. Giguere, R. Lloyd, J. McGuirk, M. S. Murali, R. M. Stone, and R. Paquette (United States). In addition, K. Gialelis served as protocol manager, and A. Zhao and E. Cormier served as protocol data managers.

Publication History

  1. Issue published online: 4 SEP 2009
  2. Article first published online: 17 JUN 2009
  3. Manuscript Accepted: 10 FEB 2009
  4. Manuscript Received: 17 DEC 2008

Funded by

  • Bristol-Myers Squibb
  • Novartis
  • Wyeth

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (297K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Brady L. Stein, B. Douglas Smith, Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors, Leukemia Research, 2011, 35, 9, 1161

    CrossRef

  2. 2
    J. P. Radich, Chronic Myeloid Leukemia 2010: Where Are We Now and Where Can We Go?, Hematology, 2011, 2010, 1, 122

    CrossRef

  3. 3
    A. Burchert, A. Neubauer, Chronische myeloische Leukämie, Der Internist, 2011, 52, 3, 283

    CrossRef

  4. 4
    Aref Al-Kali, Hagop Kantarjian, Jianqin Shan, Roland Bassett, Alfonso Quintás-Cardama, Gautam Borthakur, Elias Jabbour, Srdan Verstovsek, Susan O'Brien, Jorge Cortes, Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia, Cancer, 2011, 117, 2
    Direct Link:
  5. 5
    Paul L. McCormack, Susan J. Keam, Dasatinib, Drugs, 2011, 71, 13, 1771

    CrossRef

  6. 6
    Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Dasatinib for the treatment of chronic myeloid leukemia, Expert Review of Hematology, 2011, 4, 3, 253

    CrossRef

  7. 7
    Roberto Latagliata, Massimo Breccia, Fausto Castagnetti, Fabio Stagno, Luigiana Luciano, Antonella Gozzini, Stefano Ulisciani, Francesco Cavazzini, Mario Annunziata, Federica Sorà, Antonella Russo Rossi, Patrizia Pregno, Enrico Montefusco, Elisabetta Abruzzese, Elena Crisà, Pellegrino Musto, Mario Tiribelli, Gianni Binotto, Ubaldo Occhini, Costanzo Feo, Paolo Vigneri, Valeria Santini, Carmen Fava, Giannantonio Rosti, Giuliana Alimena, Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib, Leukemia Research, 2011, 35, 9, 1164

    CrossRef

  8. 8
    Jakob Rudzki, Dominik Wolf, Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?, Expert Review of Hematology, 2011, 4, 2, 153

    CrossRef

  9. 9
    Javier Pinilla-Ibarz, Jorge Cortes, Michael J. Mauro, Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia, Cancer, 2011, 117, 4
    Direct Link:
  10. 10
    Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Long-term outcomes in the second-line treatment of chronic myeloid leukemia, Cancer, 2011, 117, 5
    Direct Link:
  11. 11
    Ross A Okimoto, Richard A Van Etten, Navigating the road toward optimal initial therapy for chronic myeloid leukemia, Current Opinion in Hematology, 2011, 18, 2, 89

    CrossRef

  12. 12
    Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia, Leukemia & Lymphoma, 2011, 52, S1, 81

    CrossRef

  13. 13
    Paula Garland, Jane Apperley, Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia, Future Oncology, 2011, 7, 2, 201

    CrossRef

  14. 14
    Devendra K Hiwase, David T Yeung, Deborah L White, Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients, Expert Review of Hematology, 2011, 4, 3, 285

    CrossRef

  15. 15
    A. Megan Cornelison, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Outcome of Treatment of Chronic Myeloid Leukemia With Second-Generation Tyrosine Kinase Inhibitors After Imatinib Failure, Clinical Lymphoma Myeloma and Leukemia, 2011,

    CrossRef

  16. 16
    Paolo Gallipoli, Pat Shepherd, David Irvine, Mark Drummond, Tessa Holyoake, Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study, British Journal of Haematology, 2011, 155, 1
    Direct Link:
  17. 17
    Massimo Breccia, Giuliana Alimena, The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose, Expert Opinion on Pharmacotherapy, 2011, 12, 13, 2075

    CrossRef

  18. 18
    N. Skoetz, S. Kluge, I. Monsef, K. Bauer, H. Siebert, K.-A. Kreuzer, A. Engert, Twelfth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Tyrosine Kinase Inhibitors, JNCI Journal of the National Cancer Institute, 2011, 103, 4, E1

    CrossRef

  19. 19
    Xin An, Amit K. Tiwari, Yibo Sun, Pei-Rong Ding, Charles R. Ashby, Zhe-Sheng Chen, BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review, Leukemia Research, 2010, 34, 10, 1255

    CrossRef

  20. 20
    Elias Jabbour, Hagop Kantarjian, Jorge Cortes, Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?, Seminars in Hematology, 2010, 47, 4, 344

    CrossRef

  21. 21
    Meetu Agrawal, Ravin J. Garg, Hagop Kantarjian, Jorge Cortes, Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?, Current Oncology Reports, 2010, 12, 5, 302

    CrossRef

  22. 22
    Dong Hwan (Dennis) Kim, Lakshmi Sriharsha, Chul Won Jung, Suzanne Kamel-Reid, Jerald P. Radich, Jeffrey H. Lipton, Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter?, American Journal of Hematology, 2010, 85, 11
    Direct Link:
  23. 23
    Jorge Cortes, Carmino De Souza, Manuel Ayala-Sanchez, Israel Bendit, Carlos Best-Aguilera, Alicia Enrico, Nelson Hamerschlak, Katia Pagnano, Ricardo Pasquini, Luis Meillon, Current patient management of chronic myeloid leukemia in Latin America, Cancer, 2010, 116, 21
    Direct Link:
  24. 24
    Wei-Gang Tong, Hagop Kantarjian, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Gautam Borthakur, Jianqin Shan, Sherry Pierce, Mary Beth Rios, Jorge Cortes, Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction, Cancer, 2010, 116, 13
    Direct Link:
  25. 25
    Michael Osborn, Timothy Hughes, Managing imatinib resistance in chronic myeloid leukaemia, Current Opinion in Hematology, 2010, 17, 2, 97

    CrossRef

  26. 26
    Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Francis J. Giles, Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents, Leukemia & Lymphoma, 2010, 51, 8, 1399

    CrossRef

  27. 27
    Youngil Koh, Inho Kim, Sung-Soo Yoon, Byoung Kook Kim, Dae-Young Kim, Je-Hwan Lee, Kyoo-Hyung Lee, Eunkyung Park, Hyeoung-Joon Kim, Sang Kyun Sohn, Young Don Joo, Seok Jin Kim, Jooseop Chung, Ho-Jin Shin, Sung-Hyun Kim, Chul Soo Kim, Hong Suk Song, Min Kyoung Kim, Myung Soo Hyun, Jin Seok Ahn, Chul Won Jung, Seonyang Park, Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib, Annals of Hematology, 2010, 89, 7, 725

    CrossRef

  28. 28
    D Bixby, M Talpaz, Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia, Leukemia, 2010, 25, 1, 7

    CrossRef

  29. 29
    Meetu Agrawal, Ravin J. Garg, Jorge Cortes, Alfonso Quintás-Cardama, Tyrosine Kinase Inhibitors: The First Decade, Current Hematologic Malignancy Reports, 2010, 5, 2, 70

    CrossRef

  30. 30
    D. Bixby, M. Talpaz, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance, Hematology, 2009, 2009, 1, 461

    CrossRef

  31. 31
    Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Standard Management of Patients with Chronic Myeloid Leukemia,
    Direct Link:
View Full Article (HTML) Get PDF (297K)